Zhitong Finance App News, Fosun Pharmaceutical (02196.HK) issued an announcement. Recently, Suzhou Futaba Pharmaceutical Co., Ltd., a holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the “Company”), a drug registration application for compound polyethylene glycol (3350) electrolyte dispersion (hereinafter referred to as the “drug”) was approved by the State Drug Administration. The approved indications are (1) to treat chronic constipation in children aged 1 to 11; (2) to treat fecal congestion in children aged 5 to 11, that is, intractable constipation accompanied by accumulation of fecal masses in the rectum and/or colon.

Zhitong Finance App News, Fosun Pharmaceutical (02196.HK) issued an announcement. Recently, Suzhou Futaba Pharmaceutical Co., Ltd., a holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the “Company”), a drug registration application for compound polyethylene glycol (3350) electrolyte dispersion (hereinafter referred to as the “drug”) was approved by the State Drug Administration. The approved indications are (1) to treat chronic constipation in children aged 1 to 11; (2) to treat fecal congestion in children aged 5 to 11, that is, intractable constipation accompanied by accumulation of fecal masses in the rectum and/or colon.